Search
Fosnetupitant
go.drugbank.com/drugs/DB14019ApprovedInvestigationalGenerally, 25% to 30% of patients with a diagnosis of cancer receive chemotherapy as a treatment modality and 70% to 80% of these patients undergoing chemotherapy treatment may experience nausea and vomiting … Considered one of the most distressing side effects of chemotherapy, nausea and vomiting has an immense impact on the quality of life of patients receiving certain antineoplastic therapies [A32865].
Decitabine
go.drugbank.com/drugs/DB01262ApprovedInvestigational[A2263, A2264, A2265, A215317, L14962] Decitabine was developed by MGI Pharma/SuperGen Inc. and was approved by the FDA for the treatment of MDS on February 5, 2006. … Further mutations leading to increased proliferation of cancerous cells can eventually lead to secondary acute myeloid leukemia, which has a poor prognosis.
Factor XIII (human)
go.drugbank.com/drugs/DB12909ApprovedInvestigationalWhen activated by thrombin at the site of injury, the FXIII pro-enzyme is cleaved resulting in activation of the catalytic A-subunit and dissociation from its carrier B-subunit. … Factor XIII (Human), available as the commercially available product Corifact, is approved by the Food and Drug Administration for routine prophylactic treatment and peri-operative management of surgical
Prothrombin
go.drugbank.com/drugs/DB11311ApprovedInvestigationalProthrombin Complex Concentrate (Human), is indicated for the urgent reversal of acquired coagulation factor deficiency induced by Vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients with
Mixtures: Beriplex P/n 500, Beriplex P/n 1000Afamitresgene autoleucel
go.drugbank.com/drugs/DB18592ApprovedInvestigational[L51114] MAGE-A4 is an intracellular cancer-testis antigen that is overexpressed by cancer cells in synovial sarcoma. … [L51114] On August 2, 2024, the FDA granted the accelerated approval of afamitresgene autoleucel, making it the first FDA-approved TCR gene therapy and the first gene therapy for the treatment of synovial
Synonyms: AUTOLOGOUS CD4+ AND CD8+ T CELLS OBTAINED BY LEUKAPHERESIS, TRANSDUCED WITH AN HIV-DERIVED SELF-INACTIVATING (SIN) LENTIVIRAL VECTOR, ENCODING AN ENHANCED-AFFINITY T CELL RECEPTOR (TCR) SPECIFIC FOR THEDeoxycholic acid
go.drugbank.com/drugs/DB03619ApprovedInvestigationalIn April 2015, deoxycholic acid was approved by the FDA for the treatment submental fat to improve aesthetic appearance and reduce facial fullness or convexity. … It is marketed under the brand name Kybella by Kythera Biopharma and is the first pharmacological agent available for submental fat reduction, allowing for a safer and less invasive alternative than surgical
Cefazolin
go.drugbank.com/drugs/DB01327ApprovedInvestigationalA semisynthetic cephalosporin analog with broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. It attains high serum levels and is excreted quickly via the urine.
D-glucose
go.drugbank.com/drugs/DB01914ApprovedInvestigationalVet approved[A19399] It is primarily stored as starch in plants and glycogen in animals to be used in various metabolic processes in the cellular level. … [L786] Glucose is listed on the World Health Organization's List of Essential Medicines, the most important medications needed in a basic health system.
Mixtures: Dextrose and Electrolyte No. 75, Dextrose and Electrolyte No. 48Imipenem
go.drugbank.com/drugs/DB01598ApprovedInvestigationalImipenem was first approved by the FDA in November 1985 as the combination product Primaxin marketed by Merck & Co.[L7628] … [A15389] Imipenem is commonly used in combination with [cilastatin] and is now available in a triple-drug product with cilastatin and [relebactam] which was recently approved by the FDA.
Synonyms: N-formimidoylthienamycin, N-formimidoyl thienamycinSufentanil
go.drugbank.com/drugs/DB00708ApprovedInvestigationalThe sublingual form, manufactured by AcelRx Pharmaceuticals, Inc. (AcelRx), was approved on November 2, 2018 [L4717]. … It is administered by the intravenous, epidural and sublingual routes.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeSynonyms: N-(4-(Methoxymethyl)-1-(2-(2-thienyl)ethyl)-4-piperidinyl)-N-phenylpropanamide, N-(4-(Methoxymethyl)-1-(2-(2-thienyl)ethyl)-4-piperidyl)propionanilide